Biopharmaceutical developer Introgen Therapeutics reported results from a preclinical study that its INGN 241 mda-7 therapeutic can be effectively combined with radiation therapy and shows promise as a possible treatment for lung cancer.
The Austin, TX-based company reported that research presented at the American Association for Cancer Research annual conference in Washington, DC, shows that INGN 241 can work as a radiosensitizing agent and may be useful to enhance the effects of radiotherapy. The product is currently undergoing phase 1 and phase 2 clinical testing for multiple tumor types, the company said.
By AuntMinnie.com staff writersJuly 16, 2003
Copyright © 2003 AuntMinnie.com
